Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pharvaris N.V.PHVS · Entity 4374 | Chief Commercial Officer | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pharvaris N.V.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,021 |
Ending reported balance
After 2026-09-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 20,000 · Balance 65,111 F1: This is a scheduled exercise and sale from 10b5-1 trading plan. Row 2 · 2026-09-14 · Sale · Disposed 20,000 · Balance 45,111 F1: This is a scheduled exercise and sale from 10b5-1 trading plan. F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Row 3 · 2026-09-15 · Sale · Disposed 6,090 · Balance 39,021 F3: This is a scheduled sale from 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.43 · Expires 2031-07-01 | Direct | 95,000 |
Reported balance
After 2026-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-14 · Exercise / conversion · Disposed 20,000 · Balance 95,000 F4: 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This is a scheduled exercise and sale from 10b5-1 trading plan.
F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: This is a scheduled sale from 10b5-1 trading plan.
F4: 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 18:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 6,090 | $38.99 | $237,449.10 |
DisclosureSEC source: 0001193125-26-392895 · ownership.xml · nonDerivative · entry 3 Souverijns Wim · CIK 0001973529 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,021 F3 · kind: This is a scheduled sale from 10b5-1 trading plan. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 18:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.43 | $0.00 |
DisclosureSEC source: 0001193125-26-392895 · ownership.xml · derivative · entry 4 Souverijns Wim · CIK 0001973529 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 20,000 shares Expires 2031-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 18:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 20,000 | $39.31 | $786,126.00 |
DisclosureSEC source: 0001193125-26-392895 · ownership.xml · nonDerivative · entry 2 Souverijns Wim · CIK 0001973529 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,111 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 18:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 20,000 | $17.43 | $348,600.00 |
DisclosureSEC source: 0001193125-26-392895 · ownership.xml · nonDerivative · entry 1 Souverijns Wim · CIK 0001973529 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:42 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 10,000 | $29.92 | $299,163.00 |
DisclosureSEC source: 0001193125-26-231273 · ownership.xml · nonDerivative · entry 1 Souverijns Wim · CIK 0001973529 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,111 F1 · kind: This is a scheduled sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.725 to $30.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.